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Is There a Statin
Effect on Arrhythmia
and Survival in Patients With
Nonischemic Cardiomyopathy?
Goldberger et al. (1), authors of “Effects of Statin Therapy on
Arrhythmic Events and Survival in Patients with Nonischemic
Dilated Cardiomyopathy”, note that the data “strongly suggests
that statins may improve mortality in patients with nonischemic
cardiomyopathies.” Although an association has been demon-
strated between statin use and survival, it will take more data
before an effect can be attributed to statin therapy. The fact that
there is no significant difference in the number of appropriate
implantable cardioverter-defibrillator (ICD) shocks between pa-
tients treated with statins and those not treated with statins does
not support the concept that statins have a pleiotropic antiarrhyth-
mic effect.
Another factor that needs to be considered is whether statin
therapy in this study is just a marker for a better prognosis.
Although data are not presented, it is presumed that patients on
statin therapy had higher cholesterol. Studies (2,3) have shown
that higher serum total cholesterol is independently associated
with a better prognosis in patients with heart failure. Patients
without statin therapy may have had poor nutrition or some other
type of medical problem related to poor survival (4). It would be
interesting to know the albumin levels or other measures of general
nutrition in the statin and nonstatin groups.
The investigators (1) note in the limitations section of their
study that it is highly implausible to assume that hypercholester-
olemia selects a patient population at markedly lower risk. Rather
than dismissing this relationship, the inverse relationship between
heart failure mortality and cholesterol level should be considered in
any future study of possible statin effect.
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Reply
Drs. Coplan and Ramos reemphasize several important points
from our study (1). First, because this was a retrospective analysis
of a randomized clinical trial, the results must be properly tested in
a prospective clinical trial before firm conclusions can be drawn
regarding the effects of statins on survival in nonischemic cardio-
myopathy. Regarding the mechanism for the observed survival
benefit related to statin use in the DEFINITE (DEFIbrillators in
Non-Ischemic cardiomyopathy Treatment Evaluation) substudy,
Drs. Coplan and Ramos again correctly point out that the data do
not support a pure antiarrhythmic effect, as discussed in our study.
With regard to our interpretation regarding the implausibility
that statin use incidentally identified a low-risk population, it
should be noted that the subgroup treated with statins was older
and had a higher incidence of diabetes. As noted by the investi-
gators and discussed in our study, low cholesterol has been
reported to be associated with increased mortality, raising the
possibility that absence of treatment with statins represents a
selection bias for a high-risk group, perhaps due to poor nutrition.
Although cholesterol or albumin levels were not obtained on all
participants, there was no difference in body mass index between
patients treated with statins and those not treated.
Interestingly, subsequent to publication of the DEFINITE
substudy, Go et al. (2) reported reduction in mortality associated
with statin use in a large cohort study in which cholesterol levels
were only slightly lower in the group not treated with statins.
Finally, Drs. Coplan and Ramos correctly point out that future
studies should consider the potential inverse relationship between
heart failure mortality and cholesterol level. However, we believe it
is implausible that the excess mortality in this DEFINITE
substudy was related to low cholesterol in the group not treated
with statins.
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